Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
Haematologica|August 26, 2017
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescentsFrédéric Millot, Joëlle Guilhot, Meinolf Suttorp, et al.
Blood|November 15, 2007
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaSophie Archambeault, Nikki J Flores, Ayami Yoshimi, et al.
British Journal of Haematology|May 28, 2024
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study GroupHerbert Pichler, Petr Sedlacek, Roland Meisel, et al.
Materials Advances|February 4, 2026
Natural, small molecule aliphatics (cholesterol and hexadecyl palmitate) as dielectrics for low-voltage organic field effect transistorsCristian Vlad Irimia, Corina Schimanofsky, Boyuan Ban, et al.
Journal of Materials Chemistry. C|July 3, 2025
Natural waxes from plant and animal origin as dielectrics for low-voltage organic field effect transistorsCristian Vlad Irimia, Cigdem Yumusak, Yasin Kanbur, et al.
Annals of Hematology|November 12, 2022
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease courseFanny Delehaye, Jérémie Rouger, David Brossier, et al.
Blood|June 10, 2010
Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomalyAles Janda, Petr Sedlacek, Manfred Hönig, et al.
Haematologica|February 11, 2010
Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteriaEster Mejstrikova, Jana Volejnikova, Eva Fronkova, et al.
British Journal of Clinical Pharmacology|November 20, 2024
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trialsKrzysztof Kalwak, Ajay Vora, Peter Bader, et al.
Blood Advances|September 22, 2023
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM studyPeter Bader, Ulrike Pötschger, Jean-Hugues Dalle, et al.
Pageof 13